A New Cause for Concern: Cadrenal Therapeutics, Inc. Adds a New Natural and Human Disruptions Risk

Cadrenal Therapeutics, Inc. (CVKD) has disclosed a new risk, in the Natural and Human Disruptions category.

Cadrenal Therapeutics, Inc. faces significant risk from global health crises such as a resurgence of COVID-19, which could impede clinical trial operations and delay patient enrollment, particularly in their pivotal Phase 3 study. The company may incur heightened costs if additional clinical sites are needed to bolster patient recruitment. Moreover, disruptions in manufacturing and shipping of clinical materials could adversely impact supply chains, while a broader economic downturn may hinder fundraising efforts and strategic partnerships. These uncertainties underscore the potential for a global health crisis to detrimentally affect Cadrenal Therapeutics’ business and growth prospects.

The average CVKD stock price target is $4.00, implying 514.63% upside potential.

To learn more about Cadrenal Therapeutics, Inc.’s risk factors, click here.